Recruiting · registry statusDeep brain stimulation in Parkinson's dementia
Researchers are studying stimulation treatment for movement symptoms in people who also have dementia.
Testing a treatment or activity · Study reference: NL-OMON24650
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported date)
- 2021-10-01
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Age range not listed · Ask the team who can join
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: Not reported
Inclusion criteria: •age 18 years and older;
•diagnosis of PD according to the clinical diagnostic criteria of the Movement Disorder Society (MDS) (22) – see Appendix 13.3;
•despite optimal pharmacological treatment, at least one of the following symptoms, that are severe enough to impair functioning in daily life independent of dementia:
omotor response fluctuations;
odyskinesia;
opainful dystonia;
olevodopa-responsive bradykinesia;
•diagnosis of probable or possible PDD according to the MDS clinical diagnostic criteria (6) – see Appendix 13.4 (amongst others this encompasses the development of dementia áfter established diagnosis of PD). This will be based on a standardized neuropsychological examination; i.e. presence of at least 2 abnormal cognitive domains, each consisting of 2 abnormal (i.e., = 2 standard deviations) tests, so at least 4 abnormal tests in total. If a test cannot be executed due to severe cognitive difficulties the test is regarded to be abnormal;
•a life expectancy of at least two years;
•subject has decision capacity to give informed consent, judgement of which is at the discretion of an experienced neurologist from the study team (see 7.3);
•subject provides written informed consent;
•regular contact with a caregiver, who has at least approximately twice a week contact with the subject and also provides written informed consent for their own participation.
Exclusion criteria: •any neurodegenerative disorder other than PD;
•previous neurosurgery for PD (e.g., DBS, pallidotomy, thalamotomy). Nota bene: intrajejunal levodopa infusion or subcutaneous apomorphine infusion are not considered an exclusion criterion;
•contraindications for DBS surgery, such as a physical disorder making surgery hazardous;
•Hoehn and Yahr stage 4 or 5 at the best moment during the day (23);
•co-existence of another abnormality or disorder:
othat causes cognitive impairment that may improve with specific treatment; OR
othat besides PDD is judged to contribute significantly to the cognitive impairment by the treating physician;
•current major depressive episode according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (24) – see Appendix 13.5;
•current psychosis (treatment with antipsychotics is allowed);
•other severely disabling condition;
•immobility during the greater part of the day not related to off-drug phase (e.g., due to apathy);
•pregnancy, breastfeeding, and women of childbearing age not using a reliable method of contraception.
Full study name & original research details
Official study title
Deep brain stimulation for motor symptoms in patients with Parkinson’s disease dementia
Original description
Intervention:
STN-DBS
Primary outcome:
Change from baseline to 30 weeks on the Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III score (i.e., motor signs) in a standardized off-drug phase.
Secondary outcome:
The main secondary outcome measures consist of scales assessing cognitive aspects of daily living, neuropsychiatric symptoms and impulsive compulsive disorders. Additional secondary outcome measures encompass motor signs during on-drug phase, dyskinesias, motor fluctuations, cognitive performance, functional health status, incidence of falls, use of PD medication, (S)AEs, treatment satisfaction, caregiver burden, recruitment and retention rate, and medical care use.
Conditions reported: Parkinson's disease
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- Study type
- Interventional
- Interventions
- STN-DBS
- Phases
- Not reported
- Sponsor
- None
- Start date reported by registry
- 2021-10-01 (reported)
Registry updated: Not reported · Status last verified by the registry submitter: Not reported
Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Bart Swinnen · 0031650074213 · b.e.k.swinnen@amsterdamumc.nl
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
No locations reported. Ask the study team where participation is available.
The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.